Cord Blood Banking and Transplantation in a National Program: Thirteen Years of Experience
| Autor: | Karina Peñaflor, Hector Mayani, Ángel Guerra-Márquez |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Adolescent National Health Programs Umbilical cord History 21st Century Disease-Free Survival 03 medical and health sciences Young Adult 0302 clinical medicine Pregnancy Internal medicine Medicine Humans Child Survival rate Mexico Immunodeficiency Aged Retrospective Studies Leukemia business.industry Donor selection Hematopoietic Stem Cell Transplantation Infant Newborn Infant General Medicine Bone Marrow Failure Disorders Middle Aged medicine.disease Fetal Blood Transplantation Survival Rate 030104 developmental biology medicine.anatomical_structure Hemoglobinopathy 030220 oncology & carcinogenesis Cord blood Child Preschool Blood Banks Female Cord Blood Stem Cell Transplantation business |
| Zdroj: | Archives of medical research. 51(1) |
| ISSN: | 1873-5487 |
| Popis: | Background The umbilical cord blood bank at the Mexican Institute of Social Security (IMSS-CBB) was established in January 2005. This lead to the development of the UCB transplantation program. Herein, we describe the experience generated during these 13 years. Study Design and Methods Donor selection, as well as UCB collection, processing, and banking were performed under good manufacturing practices and standard operating procedures. UCB units were thawed, processed, and released for transplantation based on HLA and nucleated cell content. Results From January 2005–December 2017, 1,298 UCB units were banked; 164 of them were released for transplantation, and 118 UCB transplants were performed. Ninety-four transplants were performed in pediatric patients and 24 in adults. Sixty percent of them corresponded to patients with leukemia, 19% were patients with marrow failure, and the rest had immunodeficiency, hemoglobinopathy, metabolic disorders, or solid tumors. Engraftment was observed in 67 patients (57% of transplanted patients) and 64% of them were still alive when writing this article. In contrast, only 13 of the 51 (25%) non-engrafting patients were alive. At the time of writing this article, the disease-free survival rate was 37%, and the overall survival rate was 47%, with survival periods of 161–3,721 days. Conclusion The IMSS UCB banking and transplantation program has had a significant impact for many IMSS patients. The hematopoietic transplantation program at our institution has benefited from the use of UCB as a source of transplantable cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect